Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa + fludarabine + busulfan conditioning for allo-HSCT in adult ALL
ChiCTR2400088533Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, fludarabine and busulfan in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Disease-free survival at 1 year and 2 years post-transplantation. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
thiotepafludarabinebusulfan
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2400088533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088533.